CLINICAL TRIALS PROFILE FOR ACTIVELLA
✉ Email this page to a colleague
All Clinical Trials for ACTIVELLA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00919919 ↗ | Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen | Unknown status | Ferring Pharmaceuticals | Phase 2 | 2009-06-01 | The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer. |
NCT00919919 ↗ | Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen | Unknown status | Rabin Medical Center | Phase 2 | 2009-06-01 | The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer. |
NCT01157182 ↗ | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2007-02-01 | The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fasting conditions. |
NCT01181726 ↗ | Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2007-01-01 | The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions. |
NCT01817530 ↗ | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | Completed | AbbVie | Phase 2 | 2013-04-08 | This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids. |
NCT02693002 ↗ | Estrogen Diastolic Heart Failure | Terminated | Gretchen Wells | Phase 4 | 2016-02-01 | Peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (BNP). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACTIVELLA
Condition Name
Clinical Trial Locations for ACTIVELLA
Trials by Country
Clinical Trial Progress for ACTIVELLA
Clinical Trial Phase
Clinical Trial Sponsors for ACTIVELLA
Sponsor Name